Clinical Trials Logo

Waldenstrom's Macroglobulinemia clinical trials

View clinical trials related to Waldenstrom's Macroglobulinemia.

Filter by:

NCT ID: NCT05979948 Recruiting - Clinical trials for Waldenström's Macroglobulinemia

A Phase 2 Clinical Trial to Evaluate Zanubrutinib Combined With BR (Bendamustine/Rituximab) Regimen in Subjects With Newly-diagnosed Waldenström's Macroglobulinemia

CZ-WM01
Start date: August 1, 2023
Phase: Phase 2
Study type: Interventional

This was a single-arm, multicenter, Phase 2 study to evaluate the efficacy of zanubrutinib combined with BR (Bendamustine/Rituximab) regimen in Chinese participants with newly-diagnosed Waldenström's macroglobulinemia who exhibited one or more of the criteria for requiring treatment based on consensus guidelines from the 11th International Workshop on Waldenström's Macroglobulinemia (IWWM). The investigators propose this combination will improve the deep remission compared to single Zanubrutinib or BR regimen and can be a time-limited regimen which will reduce the life-time therapy and benefit the patients.

NCT ID: NCT05326308 Recruiting - Clinical trials for Chronic Lymphocytic Leukemia

Zanubrutinib in Patients With Waldenström's Macroglobulinemia, Chronic Lymphocytic Leukemia, Marginal Zone Lymphoma and Follicular Lymphoma

ARIADNE
Start date: April 26, 2022
Phase:
Study type: Observational

The objective of this NIS is to evaluate medical resource utilization, where data is rare in all cohorts, patient's QoL and effectiveness of zanubrutinib treatment in adult patients with WM, CLL, MZL and FL in a real-world setting.

NCT ID: NCT04274738 Completed - Clinical trials for Waldenstrom's Macroglobulinemia

A Study of Mavorixafor in Combination With Ibrutinib in Participants With Waldenstrom's Macroglobulinemia (WM) Whose Tumors Express Mutations in MYD88 and CXCR4

Start date: April 30, 2020
Phase: Phase 1
Study type: Interventional

The primary objective of the study is to establish a pharmacologically active dose of mavorixafor in combination with ibrutinib based on pooled safety, clinical response, pharmacokinetic (PK) and pharmacodynamic (PD) data to select the recommended dose for a randomized registrations trial.

NCT ID: NCT03697356 Recruiting - Clinical trials for Waldenström's Macroglobulinemia

R-VRD Followed by Lenalidomide Maintenance in Patients With Waldenstrom's Macroglobulinemia

Ballondor
Start date: March 6, 2019
Phase: Phase 2
Study type: Interventional

A multicenter prospective phase II study of rituximab combined, lenalidomide, dexamethasone followed by lenalidomide maintenance in patients with newly diagnosed Waldenström's macroglobulinemia (Ballondor trial)

NCT ID: NCT03225716 Terminated - Clinical trials for Waldenstrom's Macroglobulinemia

A Study of Ulocuplumab And Ibrutinib in Symptomatic Patients With Mutated CXCR4 Waldenstrom's Macroglobulinemia

Start date: October 20, 2017
Phase: Phase 1
Study type: Interventional

This research study is studying Ulocuplumab combined with ibrutinib as a possible treatment for symptomatic Waldenstrom's Macroglobulinemia (WM).

NCT ID: NCT03053440 Completed - Clinical trials for Waldenström's Macroglobulinemia

A Study Comparing BGB-3111 and Ibrutinib in Participants With Waldenström's Macroglobulinemia (WM)

ASPEN
Start date: January 25, 2017
Phase: Phase 3
Study type: Interventional

This study evaluated the safety, efficacy and clinical benefit of BGB-3111 (zanubrutinib) vs ibrutinib in participants with MYD88 Mutation Waldenström's Macroglobulinemia.

NCT ID: NCT02981745 Recruiting - Clinical trials for Chronic Lymphocytic Leukemia

Study of Safety,Efficacy and Pharmacokinetics of CT-1530 in Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, and Waldenstrom's Macroglobulinemia

Start date: April 1, 2017
Phase: Phase 1/Phase 2
Study type: Interventional

This is a phase I study of BTK inhibitor CT-1530 in patients with relapsed or refractory B cell non-Hodgkin lymphoma (B-NHL), chronic lymphocytic leukemia (CLL) or Waldenstrom's macroglobulinemia (WM). The purpose of the study is to determine the MTD/RP2D of CT-1530, and evaluate its safety and tolerability as monotherapy in subjects with relapsed or refractory B cell non-Hodgkin lymphoma (B-NHL), chronic lymphocytic leukemia (CLL) or Waldenstrom's macroglobulinemia (WM).

NCT ID: NCT02604511 Completed - Clinical trials for Waldenstrom's Macroglobulinemia

Study of Ibrutinib in Patients With Symptomatic, Previously Untreated Waldenstrom's Macroglobulinemia, and Impact on Tumor Genomic Evolution Using Whole Genome Sequencing

Start date: January 2016
Phase: Phase 2
Study type: Interventional

This research study is studying a drug called ibrutinib as a possible treatment for untreated Waldenstrom's Macroglobulinemia (WM).

NCT ID: NCT02566265 Completed - Multiple Myeloma Clinical Trials

Study of High-dose Influenza Vaccine Efficacy by Repeated Dosing IN Gammopathy Patients

SHIVERING 2
Start date: September 2015
Phase: Phase 2
Study type: Interventional

The investigators' hypothesis is that the administration of Fluzone® High-Dose with booster to all patients with monoclonal gammopathies (irrespective of age) will lead to seroconversion rates exceeding 50% and more importantly, will reduce influenza-related morbidity, reduce interruptions in cancer therapy and may reduce disease progression at the end of the flu season

NCT ID: NCT02439138 Suspended - Clinical trials for Waldenstrom's Macroglobulinemia

Study of Phosphatidylinositol-3-kinase (PI3K) Inhibitor Idelalisib (GS-1101) in Waldenström Macroglobulinemia

Start date: October 2015
Phase: Phase 2
Study type: Interventional

This research study is evaluating a drug called idelalisib (formerly known as GS-1101 or CAL-101) as a possible treatment for Waldenstrom's Macroglobulinemia (WM).